First Page | Meta Content | |
---|---|---|
Document Date: 2009-04-02 10:44:30Open Document File Size: 157,74 KBShare Result on FacebookCityManati / Raritan / /CompanyORTHOMcNEIL PHARMACEUTICAL INC. / Johnson & Johnson Pharmaceutical Research and Development L.L.C. / Ortho Pharmaceutical / S-037 Ortho McNeil Pharmaceutical Inc. / Johnson & Johnson / /CountryPuerto Rico / /EventFDA Phase / /FacilityRegulatory Affairs U.S. Highway / /IndustryTermsupplemental new drug applications / multi-use self-preserving aqueous solution / drug products / metal cations / food / /MedicalConditionSynovitis / severe infections / infection / MS / osteochondrosis / /OrganizationOral administration / Food and Drug Administration / Special Pathogen and Immunologic Drug Products Office / DOSAGE AND ADMINISTRATION / Center for Drug Evaluation and Research / DEPARTMENT OF HEALTH / Division of Special Pathogen / /PersonRenata Albrecht / Manisha Padhye / Robin Anderson / / /PositionDirector / Regulatory Affairs / Director / R.N. / M.D. Director / /Productlevofloxacin / Videx / sucralfate / didanosine / LEVAQUIN / S-036 / S-001 / HFD-410 / S-037 / NDAs1721 / /ProvinceOrStateNew Jersey / Maryland / /Technologypdf / /SocialTag |